Disappointed. Despite AZ, IL, LA, RI—recently passing legislation to expand access to #BiomarkerTesting, Governor Gavin Newsom vetoed this bill #SB912, despite unanimous bipartisan support. Big step backwards for CA patients and doctors. #CallOnNewsom #ctdna genomeweb.com/policy-legisla…

In the observational arm of the CIRCULATE-Japan study, among patients with stage II-IV #ColorectalCancer, those with the presence of circulating #tumorDNA post-tumor resection have a high recurrence risk & are likely to benefit from adjuvant #chemotherapy nature.com/articles/s4159…

ctDNA testing has shown great promise in solid tumors for monitoring disease progression and detecting relapse in real time. This article reports on the use of #ctDNA testing specific to anal squamous cell carcinoma. doi.org/10.1093/oncolo…

We are pleased to announced that Merck will utilize Natera’s real-world database of de-identified clinical and genomic data from more than 100,000 early- and late-stage cancer patients who have been tested with #Signatera to advance oncology research. ow.ly/rCnI50Q7v0S

Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial buff.ly/3O6YHxr Tom Powles Zoe Assaf Petros Grivas Alexey Aleshin joaquim bellmunt Sanjeev Mariathasan

We're excited to share that we have passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting #Natera’s technology in the scientific literature. 👏natera.com/company/news/n…

Patients with colon cancer with positive ctDNA tests often face tougher outcomes. Research by Dana-Farber & Brigham and Women's Hospital presented at #ASCOGI shows that treatment with a non-steroidal anti-inflammatory drug significantly boosts disease-free survival. ➡️ bit.ly/4g9zO01

ctDNA Status Is Prognostic for DFS With Celecoxib in Stage III Resected Colon Cancer Jonathan A. Nowak Brigham and Women's Hospital Brigham and Women's Pathology Dana-Farber Harvard Medical School ASCO #GI25 #crcsm #medtwitter #oncology onclive.com/view/ctdna-sta…

CALGB SWOG 80702 results to be presented today. First large scale predictive Signatera data in CRC showing benefit to adding celecoxib to SOC ACT in S3 disease. Big news for field, congrats to all involved. Luis Natera, Ph.D. #alliance #GI24 #ctdna $ntra natera.com/company/news/n…

VIDEO: Celecoxib / Celebrex & ctDNA in Stage III Colon Cancer findings from the CALGB Alliance / SWOG 80702 at ASCO GI Jonathan A. Nowak ASCO #GI25 Brigham and Women's Hospital Brigham and Women's Pathology Dana-Farber Harvard Medical School OncoAlert #Celecoxib #ctDNA #ColonCancer #ASCOGI2025 #CancerResearch #Oncology

Presented at #ESMO25: In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. Full IMvigor011 phase 3 trial